Infinity Pharmaceuticals | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Infinity Pharmaceuticals

An SI Board Since April 2006

Posts	SubjectMarks	Bans	Symbol
210	13	0	INFI

Emcee: dr.praveen	Type: Moderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
60	OT listkeeping (from the previous post) I was poking around at the companies in	Mike McFarland	-	8/2/2006
59	Chapter 7: Interviews With Industry Experts Michael Foley, Ph.D., Vice President	Mike McFarland	-	8/2/2006
58	<i>There may be an inherent limit to the efficacy of direct Hsp90 inhibiti	Mike McFarland	-	8/1/2006
57	Good point; there is plenty of competition for heat shock inhibitors--it must b	Mike McFarland	-	7/28/2006
56	kosn isn't going anywhere with hsp90. They have a lead. And have an oral dru	rkrw	-	7/27/2006
55	There might be something interesting in here for you if you haven't already	Mike McFarland	-	7/27/2006
54	>>You wonder if Kosan will walk away from their 17-aag, fall back to their	tuck	-	7/27/2006
53	You wonder if Kosan will walk away from their 17-aag, fall back to their epothil	Mike McFarland	-	7/27/2006
52	Discovery Partners International Announces Record Date for Stockholders Eligible	LJM	-	7/27/2006
51	Current Issue of Journal of Medicinal Chemistry Highlights Advantages of Infinit	LJM	-	7/27/2006
50	Risk section, page 40 of the s-4a (toward the bottom) --by the way, for those fo	Mike McFarland	-	7/25/2006
49	Here's one patent freshpatents.com The present invention provides analogs o	Mike McFarland	-	7/24/2006
48	A successful cancer-fighting drug may also damage the heart, although a research	dr.praveen	-	7/24/2006
47	[Design, Synthesis, and Biological Evaluation of Hydroquinone Derivatives of 17-	tuck	-	7/21/2006
46	Infinity Announces Extension of Amgen Agreement Thursday July 20, 8:54 am ET CA	nigel bates	-	7/20/2006
45	<i>Bauer and Fletcher presented a preclinical evaluation of IPI-504 in GIS	Mike McFarland	-	7/4/2006
44	Here are the descriptions for each of those, IPI-504 is at #9 off the GIST suppo	Mike McFarland	-	7/4/2006
43	ACS Chem. Biol. 1 (5), 279–284 Tumor Selectivity of Hsp90 Inhibitors: The Expla	Mike McFarland	-	7/4/2006
42	See the Keryx and Kosan threads for glowing reviews of their drugs for MM. Ande	Mike McFarland	-	7/3/2006
41	MM Research Consortium themmrc.org Multiple Myeloma Genomic Initiative themmrc.	Mike McFarland	-	7/2/2006
40	MMRF Spring Newsletter, page nine has a list of emerging therapies for MM multi	Mike McFarland	-	7/2/2006
39	Here is an abstract that describes the mouse experiment (RPMI-8226 human MM cell	Mike McFarland	-	6/19/2006
38	I'm contemplating purchasing this article, I've pointed to it once befor	Mike McFarland	-	6/13/2006
37	Reverse mergers attract top-tier biotechs in sluggish IPO market Nature.com (sub	Mike McFarland	-	6/4/2006
36	pages F-69,70 detail the convertible preferred stock, I assume that Amgen, Nova	Mike McFarland	-	5/25/2006

Go to reply# or date (mm/dd/yy):